The Prime Minister of Canada, Justin Trudeau, spoke out clearly in favour of legalizing marijuana during the election campaign that brought him to power on October 19. Professor Serge Brochu of University of Montreal's School of Criminology would support this policy change and has answered several questions to clarify the rational and nuance surrounding his opinion.

Q: What are the arguments in favour of legalization?

Dany Lefebvre has a sleek, modern production facility set up near Drummondville, Que. with a state-of-the art ventilation system, heat lamps and high security.

All he needs now is the green light from the new Liberal government to grow marijuana in it.

"We know they'll have four years," Lefebvre said from the headquarters of Vert Médical in St-Lucien, 130 kilometres east of Montreal.

"In my opinion, it'll definitely be implemented in that time."

Lefebvre is among many entrepreneurs across Canada eagerly awaiting a Liberal proposal to legalize marijuana become reality.

He has close to 40 hectares of land primed for planting hemp.  In addition, he hopes to grow high-quality marijuana in his indoor facility.

There will be more change than just a cloud of smoke over the city.

Let’s be real here people, one of the most appealing aspects of Justin Trudeau/the Liberal Party’s platform for a lot of us youths (at least the stoner ones) was the promise to legalize marijuana. During Harper’s reign, the idea of legal marijuana in Canada was but a fantasy, but now that Trudeau is in the house (of Commons) we may actually see a nation where marijuana use is no longer against the law.

OAKVILLE, ON--(Marketwired - Oct 20, 2015) -Canadian Cannabis Corp. (CCC) (OTC PINK: CCAN) plans to acquire Hydropothecary Corporation, a licensed producer of cannabis and cannabis oils and licensed distributor of Medicinal Marijuana under the Marijuana for Medical Purposes Regulations (MMPR - license link).

The parties have agreed to general terms, where CCC will pay a total consideration of $21.3 million in cash and stock ($28 million CAD) for 100% ownership in Hydropothecary. CCC has paid an initial $500,000 as a deposit, with the transaction expected to close on November 17, 2015.

• First study has shown cannabis can help slow rejection of new organs 
• Active ingredient THC slows the immune response, delaying rejection
• Could pave the way for new anti-rejection therapies, scientists hope 

Cannabis could help the body accept foreign organs during transplant operations, scientists have discovered.

The active ingredient in marijuana, tetrahydrocannabinol or THC, may help delay the rejection of incompatible organs.

It may, therefore, prove useful as an anti-rejection therapy, particularly in situations where transplanted organs may not be a perfect match.

The issue of the niqab in Canadian citizenship ceremonies roared to life again in Friday’s leadership debate with Tom Mulcair trying to fight his way out of a political corner by accusing the prime minister of using the issue for political reasons.

The debate also featured a ferocious battle about values with Liberal Leader Justin Trudeau demanding Stephen Harper state once and for all whether he is pro-choice. Harper retaliated by accusing him of setting a bad example to youth because the Liberals want to legalize marijuana.

Patients with chronic pain who used cannabis daily for one year did not have an increase in serious adverse events compared to pain patients who did not use cannabis, according to a new study.

“This is the first and largest study of the long term safety of medical cannabis use by patients suffering from chronic pain ever conducted,” says lead author Mark Ware, associate professor of family medicine and anesthesia at McGill University.

“We found that medical cannabis, when used by patients who are experienced users, and as part of a monitored treatment program for chronic pain over one year, appears to have a reasonable safety profile.”

A new study conducted on the medical consumption of cannabis came up with some good news, and some bad news: for starters, while there were some adverse effects on consumers, no serious effects were reported. However, the reduction in pain also seems to be very small.

Montreal, September 29, 2015-- A Canadian research team led by Dr. Mark Ware from the Research Institute of the McGill University Health Centre (RI-MUHC) in Montréal has completed a national multicentre study looking at the safety of medical cannabis use among patients suffering from chronic pain. They found that patients with chronic pain who used cannabis daily for one year, when carefully monitored, did not have an increase in serious adverse events compared to pain patients who did not use cannabis. The results, which have been published online in The Journal of Pain, will serve as a benchmark study on the side effects of cannabis when used in pain management.

A new study, Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS), is being published in the Journal of Pain and found that patients who used marijuana daily for one-year reported reduced discomfort and increased quality of life.

The study also found that patients do not experience an increased risk of serious side effects, and that patients who used marijuana had a reduced sense of pain when compared to a control group, as well as reduced anxiety, depression, and fatigue.